All In Biotech

Drug Trial Radar · NCT04025957

A Study of SHR-1501 in Patients With Advanced Tumors

A Phase I Study on Tolerance, Safety and Pharmacokinetics of SHR-1501 in Patients With Advanced Malignancies.

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Oct 30, 2019

Primary completion

Jul 31, 2022

Study completion Jul 31, 2022

Sponsor

Sponsor type
Industry
First posted
Jul 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in patients with advanced malignancies .

Conditions

  • Advanced Malignancies

Interventions

  • SHR-1501Drug

    Administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicityTime frame: Approximately 2 years
  2. Maximum tolerated doseTime frame: Approximately 2 years
  3. Adverse event/Serious adverse eventTime frame: Approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer hospital, Chinese academy of medical sciences

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.